Human Muscle Gene Expression Profiles in Young and Old Men (CERA)

This study has been completed.
Sponsor:
Collaborators:
Fondation des Caisses d'Epargne Rhône-Alpes
Institut National de la Recherche Agronomique
Information provided by:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT00725166
First received: July 29, 2008
Last updated: June 9, 2009
Last verified: June 2009
  Purpose

To reach the goals of living longer in better medical conditions, many countries reach the same conclusion: new strategies have to be developed to avoid, or at least limit, the effects of age; this requires a better knowledge of the mechanisms of aging. Our project focuses on the loss of muscle mass associated with aging, called sarcopenia. Sarcopenia unavoidably leads to impaired mobility and poor balance, which contributes to loss of functional autonomy and to increased prevalence for severe falls. Skeletal muscle also plays a central role as a reserve for energy and amino acids. Hence, sarcopenia further triggers severe side metabolic effects such as frailty among elderly persons. The precise mechanisms of muscle aging are still mostly unknown, although many theories have been proposed.

The present study aims at better understanding the mechanisms of skeletal muscle loss associated with aging. Using muscle biopsies from young and old subjects, the differential expression profiles of mRNA will be obtained through chips that will evaluate more than 39000 transcripts. On the same samples, proteomic analyses will involve two complementary approaches: (1) bidimensional electrophoresis (2DGE) coupled to mass spectrometry (MALDI-ToF) for dominant proteins; (2) Western-blot (more than 800 antibodies) targeting regulating proteins not detectable using 2DGE. Complementary histological studies (immunohisto-fluorescence, confocal microscopy) will specify the localisation of the major biomarkers in the muscle biopsies.

The results of that research will have applications in the medium term and will lead to nutritional interventions to modulate specific metabolic pathways and improve the quality of life in the elderly.


Condition Intervention
Elderly
Sarcopenia
Other: Skeletal muscle aging

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Human Muscle Gene Expression Profiles in Young and Old Men

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire de Saint Etienne:

Primary Outcome Measures:
  • To identify the differential expression profiles (proteomics, transcriptomics) in skeletal muscle between young and old men [ Time Frame: During biopsie (W3) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To specify the localisation of the major biomarkers in the muscle biopsies. [ Time Frame: During biopsie (W3) ] [ Designated as safety issue: No ]
  • To compare muscular energy metabolic enzymatic activities between young and old men [ Time Frame: during biopsie (W3) ] [ Designated as safety issue: No ]
  • To compare the number of muscular stem cells between young and old men [ Time Frame: during biopsie (W3) ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Serum, muscle


Enrollment: 41
Study Start Date: October 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Young
Young men 19-25 years old
Other: Skeletal muscle aging

W1 - Blood test

  • Maximal voluntary contraction of quadriceps
  • Hydrostatic weighing

W2 - Maximal metabolic test using a cycloergometer

W3 - Muscular biopsy

Old
old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
Other: Skeletal muscle aging

W1 - Blood test

  • Maximal voluntary contraction of quadriceps
  • Hydrostatic weighing

W2 - Maximal metabolic test using a cycloergometer

W3 - Muscular biopsy


  Eligibility

Ages Eligible for Study:   19 Years to 76 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Young : students of the Saint-Etienne's university. Old : men who participate in the PROOF study

Criteria

Inclusion Criteria:

  • Affiliated or beneficiary of a social security category
  • Having signed the inform consent form
  • Having signed the genetic consent form

Exclusion Criteria:

  • Antiaggregant platelet treatment
  • Type 2 diabetes
  • Body Mass Index > 25
  • Severe renal disease
  • CRP > 10
  • Abnormal clotting test
  • Allergies to local anesthetics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00725166

Locations
France
CHU de Saint-Etienne
Saint-etienne, France, 42000
Sponsors and Collaborators
Centre Hospitalier Universitaire de Saint Etienne
Fondation des Caisses d'Epargne Rhône-Alpes
Institut National de la Recherche Agronomique
Investigators
Study Chair: Daniel BECHET, PhD INRA Clermont-Ferrand
Principal Investigator: Jean-Claude BARTHELEMY, MD PhD CHU de Saint-Etienne
  More Information

No publications provided

Responsible Party: Clément CAILLAUX, CHU de Saint-Etienne
ClinicalTrials.gov Identifier: NCT00725166     History of Changes
Other Study ID Numbers: 0708102, 2008-A00374-51
Study First Received: July 29, 2008
Last Updated: June 9, 2009
Health Authority: France: Ministry of Health
France: Direction Générale de la Santé
France: French Data Protection Authority

Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
Aging
Biopsy
Skeletal muscle
Molecular biology
Genetic markers
Gene expression regulation
Young and old men
Healthy volunteers

Additional relevant MeSH terms:
Sarcopenia
Atrophy
Muscular Atrophy
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Manifestations
Pathological Conditions, Anatomical
Signs and Symptoms

ClinicalTrials.gov processed this record on October 23, 2014